Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

FDA grants Orphan Drug Designation to Alexion Pharmaceuticals Inc 's Soliris (eculizumab)


Tuesday, 17 Jun 2014 06:39am EDT 

Alexion Pharmaceuticals Inc:Says U.S. FDA has granted orphan drug designation (ODD) to Soliris.Soliris (eculizumab) used for treatment of patients with Myasthenia Gravis (MG), a rare, debilitating neurologic disorder caused by uncontrolled complement activation.In patients with MG, uncontrolled complement activation due to antibodies directed at neuromuscular junction can ultimately lead to profound and debilitating weakness of various muscle groups throughout body.Oliris is first-in-class terminal complement inhibitor and is currently approved for treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation. 

Company Quote

182.08
4.35 +2.45%
17 Dec 2014